Pasithea's PAS-004 shows prolonged stable disease in four patients in Phase 1 cancer trial

Bitget2026/10/23 13:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pasithea Therapeutics is presenting results from its ongoing Phase 1 PAS-004 cancer trial today at ESMO Congress 2026 in Madrid.
The 37-patient study showed prolonged stable disease in four heavily pretreated patients, including two with melanoma that progressed on prior targeted therapy.
Treatment-related side effects were mild or moderate, with no treatment discontinuations or serious treatment-related adverse events reported.
No dose-limiting toxicities occurred, while the drug’s pharmacokinetic profile supported long-term, once-daily dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230915PRIMZONEFULLFEED9851813) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pasithea's PAS-004 shows prolonged stable disease in four patients in Phase 1 cancer trial

You may also like

Crypto prices